Grace Therapeutics (GRCE) Cash from Financing Activities (2019 - 2025)

Grace Therapeutics has disclosed Cash from Financing Activities across 6 years of filings, most recently posting $4.0 million for Q4 2025.

• In Q4 2025, Cash from Financing Activities changed N/A year-over-year to $4.0 million; the TTM figure through Jun 2026 stood at $4.0 million (down 70.52% YoY), while the FY2026 annual figure was $3.7 million, down 73.54% from the prior year.
• Cash from Financing Activities came in at $4.0 million for Q4 2025 at Grace Therapeutics, up from -$327000.0 in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $34.7 million in Q1 2021 to a low of -$327000.0 in Q2 2025.
• Average Cash from Financing Activities over 4 years is $8.6 million, with a median of $4.0 million recorded in 2025.
• Year-over-year, Cash from Financing Activities soared 163.19% in 2021 and soared 6651.38% in 2023.
• Over 4 years, Cash from Financing Activities stood at $34.7 million in 2021, then tumbled by 99.69% to $109000.0 in 2022, then soared by 6651.38% to $7.4 million in 2023, then tumbled by 45.1% to $4.0 million in 2025.
• Per Business Quant data, the three most recent Cash from Financing Activities figures were $4.0 million in Q4 2025, -$327000.0 in Q2 2025, and $14.0 million in Q1 2025.